Guided Therapeutics, Inc. (GTHP)
OTCMKTS · Delayed Price · Currency is USD
0.3500
-0.0399 (-10.23%)
At close: Feb 18, 2026

Guided Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
0.180.010.10.010.080.1
Revenue Growth (YoY)
368.42%-92.86%653.85%-83.95%-20.59%183.33%
Cost of Revenue
0.070.010.060.080.06-0.04
Gross Profit
0.1100.04-0.070.020.14
Selling, General & Admin
1.551.582.533.192.311.05
Research & Development
0.480.530.230.080.070.14
Operating Expenses
2.042.112.753.272.381.2
Operating Income
-1.93-2.11-2.72-3.33-2.36-1.05
Interest Expense
-0.57-0.38-0.28-0.58-1.15-1.06
Interest & Investment Income
-00.01---
Other Non Operating Income (Expenses)
0.29-0.040.040.862.13
EBT Excluding Unusual Items
-2.2-2.49-2.95-3.87-2.650.02
Other Unusual Items
-0.340.07-0.54-0.470.58-0.3
Pretax Income
-2.63-2.42-3.49-4.34-2.07-0.28
Net Income
-2.63-2.42-3.49-4.34-2.07-0.28
Preferred Dividends & Other Adjustments
0.170.170.270.630.360.12
Net Income to Common
-2.8-2.59-3.76-4.97-2.43-0.4
Shares Outstanding (Basic)
735751331311
Shares Outstanding (Diluted)
735751331311
Shares Change (YoY)
31.78%12.14%57.30%142.99%24.24%226.07%
EPS (Basic)
-0.04-0.05-0.07-0.15-0.18-0.04
EPS (Diluted)
-0.05-0.05-0.07-0.15-0.18-0.04
Free Cash Flow
-1.11-1.12-1.75-1.51-1.61-1.88
Free Cash Flow Per Share
-0.01-0.02-0.03-0.05-0.12-0.17
Gross Margin
62.36%28.57%36.73%-24.69%140.20%
Operating Margin
-1081.80%-30114.29%-2773.29%-25638.46%-2916.05%-1031.37%
Profit Margin
-1575.28%-37014.29%-3835.71%-38246.15%-3001.24%-393.14%
Free Cash Flow Margin
-624.16%-15985.71%-1781.63%-11615.39%-1982.72%-1839.22%
EBITDA
-1.92-2.1-2.71-3.33-2.36-1.03
D&A For EBITDA
0.010.010.01000.02
EBIT
-1.93-2.11-2.72-3.33-2.36-1.05
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.